Hölig P - Search Results

1

Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105).

Völkel T, Hölig P, Merdan T, Müller R, Kontermann RE. Völkel T, et al. Among authors: holig p. Biochim Biophys Acta. 2004 May 27;1663(1-2):158-66. doi: 10.1016/j.bbamem.2004.03.007. Biochim Biophys Acta. 2004. PMID: 15157618 Free article.

2

Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells.

Hölig P, Bach M, Völkel T, Nahde T, Hoffmann S, Müller R, Kontermann RE. Hölig P, et al. Protein Eng Des Sel. 2004 May;17(5):433-41. doi: 10.1093/protein/gzh055. Epub 2004 Jul 2. Protein Eng Des Sel. 2004. PMID: 15235124

3

Isolation from phage display libraries of lysine-deficient human epidermal growth factor variants for directional conjugation as targeting ligands.

Bach M, Hölig P, Schlosser E, Völkel T, Graser A, Müller R, Kontermann RE. Bach M, et al. Among authors: holig p. Protein Eng. 2003 Dec;16(12):1107-13. doi: 10.1093/protein/gzg145. Protein Eng. 2003. PMID: 14983093

4

What is the mechanism behind increased permeation rate of a poorly soluble drug from aqueous dispersions of an amorphous solid dispersion?

Frank KJ, Westedt U, Rosenblatt KM, Hölig P, Rosenberg J, Mägerlein M, Fricker G, Brandl M. Frank KJ, et al. Among authors: holig p. J Pharm Sci. 2014 Jun;103(6):1779-86. doi: 10.1002/jps.23979. Epub 2014 Apr 24. J Pharm Sci. 2014. PMID: 24764046

5

The amorphous solid dispersion of the poorly soluble ABT-102 forms nano/microparticulate structures in aqueous medium: impact on solubility.

Frank KJ, Westedt U, Rosenblatt KM, Hölig P, Rosenberg J, Mägerlein M, Fricker G, Brandl M. Frank KJ, et al. Among authors: holig p. Int J Nanomedicine. 2012;7:5757-68. doi: 10.2147/IJN.S36571. Epub 2012 Nov 12. Int J Nanomedicine. 2012. PMID: 23166440 Free PMC article.

6

Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: true supersaturation vs. apparent solubility enhancement.

Frank KJ, Rosenblatt KM, Westedt U, Hölig P, Rosenberg J, Mägerlein M, Fricker G, Brandl M. Frank KJ, et al. Among authors: holig p. Int J Pharm. 2012 Nov 1;437(1-2):288-93. doi: 10.1016/j.ijpharm.2012.08.014. Epub 2012 Aug 20. Int J Pharm. 2012. PMID: 22951865

7

Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound.

Frank KJ, Westedt U, Rosenblatt KM, Hölig P, Rosenberg J, Mägerlein M, Brandl M, Fricker G. Frank KJ, et al. Among authors: holig p. Eur J Pharm Sci. 2012 Aug 30;47(1):16-20. doi: 10.1016/j.ejps.2012.04.015. Epub 2012 May 1. Eur J Pharm Sci. 2012. PMID: 22579958

8

In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier.

Kanzer J, Tho I, Flaten GE, Mägerlein M, Hölig P, Fricker G, Brandl M. Kanzer J, et al. Among authors: holig p. J Pharm Pharmacol. 2010 Nov;62(11):1591-8. doi: 10.1111/j.2042-7158.2010.01172.x. J Pharm Pharmacol. 2010. PMID: 21039543

9

In situ formation of nanoparticles upon dispersion of melt extrudate formulations in aqueous medium assessed by asymmetrical flow field-flow fractionation.

Kanzer J, Hupfeld S, Vasskog T, Tho I, Hölig P, Mägerlein M, Fricker G, Brandl M. Kanzer J, et al. Among authors: holig p. J Pharm Biomed Anal. 2010 Nov 2;53(3):359-65. doi: 10.1016/j.jpba.2010.04.012. Epub 2010 Apr 24. J Pharm Biomed Anal. 2010. PMID: 20447794

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters